Safety Study on the Effect of Eurartesim™ on QT/QTc Interval Compared to Riamet in Healthy Volunteers
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The aim of such a study is to evaluate the impact of a therapeutic dose of Eurartesim™
compared to Riamet®, after multiple dose administration for 3 days in healthy male and female
subjects on electrocardiographic parameters.
Phase:
Phase 1
Details
Lead Sponsor:
sigma-tau i.f.r. S.p.A.
Collaborator:
Medicines for Malaria Venture
Treatments:
Artemether Artemether-lumefantrine combination Artemether, Lumefantrine Drug Combination Artemisinins Artenimol Dihydroartemisinin Fluoroquinolones Lumefantrine Moxifloxacin Norgestimate, ethinyl estradiol drug combination Piperaquine